| Literature DB >> 32661716 |
Vincenzo Di Stefano1, Giuseppe Battaglia2, Valerio Giustino2, Andrea Gagliardo3, Michele D'Aleo3, Ottavio Giannini2, Antonio Palma2, Filippo Brighina3.
Abstract
BACKGROUND: Quarantine was the measure taken by governments to control the rapid spread of COVID-19. This restriction resulted in a sudden change in people's lifestyle, leading to an increase in sedentary behavior and a related decrease in the practice of physical activity (PA). However, in neuromuscular diseases patients need to perform regular PA to counteract the negative consequences of the disease. Hence, the aim of this study was to estimate the levels of PA, measured as energy expenditure (MET-minute/week), among patients with neuromuscular disease (NMD) before and during the last week of quarantine.Entities:
Keywords: COVID-19; Coronavirus pandemic; Lockdown; Neuromuscular; Physical activity; Quarantine
Year: 2020 PMID: 32661716 PMCID: PMC7356123 DOI: 10.1007/s00415-020-10064-6
Source DB: PubMed Journal: J Neurol ISSN: 0340-5354 Impact factor: 4.849
Demographics and MET levels in patients with neuromuscular disease and healthy controls
| NMD | Healthy controls | ||
|---|---|---|---|
| Age (years) | 57.3 ± 13.7 | 56 ± 6.8 | 0.2 |
| Gender (males) | 93/149 (62%) | 74/119 (62%) | 0.93 |
| BMI (kg/m2) | 27.26 ± 4.4 | 26.3 ± 2.4 | 0.044* |
| MET-vigorous pre COVID-19 (min/wk) | 70.1 ± 361.9 | 2081.8 ± 4945.3 | < 0.0001*** |
| MET-vigorous during COVID-19 (min/wk) | 37.1 ± 303.9 | 861.9 ± 1662.9 | < 0.0001*** |
| ∆MET-vigorous (min/wk) | − 33 ± 219.2 | − 1219.9 ± 4920.8 | < 0.0001*** |
| MET-moderate pre COVID-19 (min/wk) | 263.2 ± 606.9 | 1153.3 ± 2424.6 | < 0.0001*** |
| MET-moderate during COVID-19 (min/wk) | 146.9 ± 450.6 | 925.4 ± 3675.6 | < 0.0001*** |
| ∆MET-moderate (min/wk) | − 116.2 ± 323.2 | − 227.87 ± 4076.9 | 0.47 |
| MET-walking pre COVID-19 (min/wk) | 547.7 ± 733.2ª | 1271.5 ± 2703.6 | 0.028* |
| MET-walking during COVID-19 (min/wk) | 211.9 ± 534 ª | 574.9 ± 1731.3 | 0.006** |
| ∆MET-walking (min/wk) | − 335.8 ± 524.3ª | − 696.5 ± 3167.1 | 0.6 |
| MET-total pre COVID-19 (min/wk) | 901.3 ± 1299.6ª | 4506.5 ± 7600.1 | < 0.0001*** |
| MET-total during COVID-19 (min/wk) | 400.6 ± 1088.5ª | 2362.3 ± 4498.9 | < 0.0001*** |
| ∆ MET-total (min/wk) | − 500.7 ± 705.7ª | − 2144.3 ± 8630.7 | 0.006** |
| MPVA pre COVID-19 (min/wk) | 333.3 ± 483.8 | 3235.7 ± 3684.7 | < 0.0001*** |
| MPVA during COVID-19 (min/wk) | 184 ± 440.3 | 1787.3 ± 2669.3 | < 0.0001*** |
| ∆MET-MPVA (min/wk) | − 149.3 ± 426.8 | − 1447.8 ± 7611.3 | 0.006** |
NMD patients with neuromuscular disease
ªcalculated only in NMD with preserved walking
*Mann–Whitney U test, p < 0.05
**Mann–Whitney U test, p < 0.01
***Mann–Whitney U test, p < 0.001
Fig. 1The figure shows the entity of MET reduction for walking (a) and moderate energy expenditure (b) and SF-12 scores (c, d) depending on the disease subtype. MY acquired or hereditary myopathy, ND genetically-confirmed degenerative disease, NJD disorder of the neuromuscular junction, PN acquired or hereditary polyneuropathy, PCS-12 physical health component score of SF-12, MCS-12 mental health component score of SF-12. *p < 0.05